12:00 AM
Feb 14, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rubitecan (RFS 2000): Phase III study update

SuperGen Inc. (SUPG), San Ramon, Calif.
Product: Rubitecan (RFS 2000)
Business: Cancer
Therapeutic category: Cell...

Read the full 58 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >